Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies

Clicks: 18
ID: 332555
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #56 of 146 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 146 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aldosterone, the terminal effector of the renin-angiotensin-aldosterone system, regulates sodium retention, potassium excretion, and blood pressure. Beyond these classical effects, aldosterone-associated and mineralocorticoid receptor (MR)-mediated signaling is implicated in inflammation, oxidative stress, fibrosis, albuminuria, and progressive cardiorenal injury, while its synthesis is regulated by factors beyond angiotensin II. This is particularly relevant in chronic kidney disease (CKD), where persistent renin-angiotensin system (RAS) activation, impaired potassium handling, reduced Klotho, altered aldosterone clearance, and incomplete suppression may sustain aldosterone exposure and MR activation despite conventional RAS blockade. These mechanisms may contribute to residual cardiorenal risk despite standard-of-care therapy. Mineralocorticoid receptor antagonist (MRA) outcome trials establish MR signaling as a therapeutic target in defined CKD populations, but therapeutic benefit from MR blockade should not be interpreted as evidence of biochemical aldosterone excess in all treated patients. This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs). We discuss aldosterone-associated and MR-mediated kidney injury, the cardiorenal axis, albuminuria as a downstream marker of injury and treatment response, and current and emerging therapeutic strategies, including steroidal and non-steroidal MRAs, ASIs, and combinations with SGLT2 inhibitors. Whereas MRA therapy has established outcome benefits in defined CKD populations, cardiorenal outcome benefit from ASIs remains unestablished; EASi-KIDNEY was discontinued early after independent Data Monitoring Committee review, with detailed results pending.
Reference Key
openalex_W7222615936 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mehmet Kanbay, Rama AlShiab, Ermeena Shah, Anas Abdo, Alberto Ortíz, Francesca Mallamaci, Carmine Zoccali
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag243
URL
https://doi.org/10.1093/ndt/gfag243
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.